Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
250 participants
INTERVENTIONAL
2018-04-09
2032-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)
NCT02851576
A Clinical Study to Enable Process Validation of Commercial Grade OTL-101
NCT04140539
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
NCT06798298
Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
NCT03000244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants receiving ADP adoptive cell therapy
ADP adoptive cell therapy
No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADP adoptive cell therapy
No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adaptimmune
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adaptimmune
Role: STUDY_DIRECTOR
Adaptimmune
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory University School of Medicine
Atlanta, Georgia, United States
ADP Investigational Site
Baltimore, Maryland, United States
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center - New York
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Froedtert Hospital
Milwaukee, Wisconsin, United States
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Klinikum rechts der Isar der Technischen Universität München
Munich, Bavaria, Germany
Uniklinik Köln
Cologne, North Rhine-Westphalia, Germany
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, , Netherlands
Hospital Universitario Virgen del Rocío
Seville, , Spain
University College London Hospitals NHS Foundation Trust
London, , United Kingdom
ADP Investigational Site
Manchester, , United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADP-0000-002
Identifier Type: OTHER
Identifier Source: secondary_id
208750
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.